TCTR20200325002已完成2 期
Immunogenicity of a combined Diphtheria-Tetanus-recombinant acellular pertussis (DTaP) vaccine in healthy toddlers
Vaccine Trial Centre (VTC), Faculty of Tropical Medicine, Mahidol Uiversity0 个研究点目标入组 290 人开始时间: 2020年3月25日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 290
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 15 Months 至 36 Months（—）
- 性别
- All
入选标准
- •Participants will be eligible for inclusion if ALL of the following criteria are met at the time of screening:
- •1. 15 to 36 months of age at the time of vaccination
- •2. Having completed the 3-dose DTwP or 3-dose DTaP vaccination (no interchange of DTwP and DTaP during primary immunization)
- •3. The parents or legal guardians of the participant are able to read and write.
- •4. The parents or legal guardians can provide written informed consent
- •5. Healthy, as established by pertinent medical history and physical examination.
排除标准
- •A participant with ANY of the following criteria at study entry will not be eligible for participation:
- •1. History of any significant medical illness such as, but not limited to, immune deficiency, renal, hepatic, cardiovascular, or endocrine disorder as determined by the investigator based on medical history and physical examination.
- •2. History of allergy or hypersensitivity to any vaccine (including its component).
- •3. History of any serious adverse event or neurological adverse event after vaccination.
- •4. Having received only 1 or 2 doses of DTwP or DTaP (incomplete primary immunization) after birth until the study enrollment.
- •5. Having received the 4th dose DTwP or DTaP vaccination.
- •6. Having experienced a physician diagnosed diphtheria or tetanus or pertussis illness within 1 year prior to recruitment.
- •7. Receipt of any vaccine within 28 days prior to enrollment (3 months for live-attenuated vaccines).
- •8. Planning to receive tetanus, diphtheria, pertussis or planning to participate in another clinical trial during the study period (approximately 1 year).
- •9. Receipt of blood or blood component or immunoglobulin within 3 months prior to recruitment.
- •10. History of receiving any immunosuppressive drug or systemic corticosteroid (more than 0.5 mg/kg of prednisolone or equivalent for more than 14 days) within 3 months prior to recruitment.
- •11. Any bleeding disorder.
- •12. Any abnormality of splenic or thymic function.
- •13. Any progressive or severe neurological disorder such as seizure disorder or Guillain-Barre syndrome;
- •14. History of any illness including cognitive impairment and psychiatric disease that, in the opinion of the investigator, might interfere with the results of the study or pose additional risk to the participants due to participation in the study.
- •15. Fever as defined by body temperature more than 38 degree celsius at the time of enrollment (temporary exclusion criterion).
研究者
相似试验
招募中
不适用
Immune response after diphtheria and tetanus toxoid booster in patients with adult onset immunodeficiency with anti-interferon gamma autoantibodyInterferon gamma autoantibodyinterferon gamma autoantibodyDiphtheria toxoidTetanus toxoidImmune responseTCTR20190422001Ratchadapiseksompoch funds36
进行中（未招募）
不适用
Immunogenicity and safety of a tetanus, diphtheria and mono component acellular pertussis (TdaP) vaccine in comparison to a tetanus and diphtheria (Td) vaccine when given as a booster vaccination to adultsThe intended use of the vaccine in this study is to increase the immunological protection against pertussis in adults who completed primary vaccination with diphtheria, tetanus and pertussis vaccine typically during their childhood.MedDRA version: 12.0Level: LLTClassification code 10034738Term: PertussisEUCTR2009-013411-36-DKStatens Serum Institut
进行中（未招募）
不适用
Safety and Immunogenicity of ADACEL™ (TdcP Vaccine) Compared with QUADRACEL™ (HCPDT-mIPV Vaccine) as Fifth Dose in Children 4-6 Years of AgeEUCTR2015-005589-43-Outside-EU/EEASanofi Pasteur Limited600
已完成
不适用
Effect and safety of Diphteria-Pertussis-Tetanus vaccine among healthcare workersPertussisJPRN-UMIN000021495Yokohama City University Medical Center150
已完成
不适用
Evaluation of the immune system response to Diphtheria and Tetanus vaccination in HIV positive patientsHIV AIDS.Human immunodeficiency virus [HIV] disease resulting in infectious and parasitic diseasesIRCT201211204076N8Resaerch Deputy tehran university of medical sciences300